This “Acute Liver Failure - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Acute Liver Failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Acute liver failure is an uncommon condition in which rapid deterioration of liver function results in coagulopathy. Acute liver failure is loss of liver function that occurs rapidly - in days or weeks. Acute liver failure, also known as fulminant hepatic failure, can cause serious complications, including excessive bleeding and increasing pressure in the brain. Signs and Symptoms of Acute liver failure include: pain in right abdomen, yellowing of skin, nausea, vomiting, sleepiness and disorientation of confusion. Tests and procedures used to diagnose acute liver failure include: blood tests and imaging tests for the examination of liver. When acute liver failure cannot be reversed the only treatment may be the liver transplant.
"Acute Liver Failure - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wilson's Disease pipeline landscape is provided which includes the disease overview and Acute Liver Failure treatment guidelines. The assessment part of the report embraces, in depth Acute Liver Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Liver Failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Acute Liver Failure R&D. The therapies under development are focused on novel approaches to treat/improve Acute Liver Failure.
This segment of the Acute Liver Failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hepastem: Promthera Biosciences
HepaStem is Promethera's lead cell therapy product currently in Phase 2 clinical trials for Acute Liver Failure. It consists of human allogeneic liver-derived medicinal signaling cells that are obtained from healthy, ethically donated organs and expanded in the manufacturing GMP factory. HepaStem is administered as a simple peripheral intravenous infusion, after which it is transported via the bloodstream to the liver, where it is expected to act as a cargo and activate multiple key pathogenetic pathways.
TAK-242: Akaza Biosciences
Akaza Bioscience is preparing to run a Phase II study of TAK-242, a novel immunological therapy. TAK-242 is an innovative, novel treatment option which aims to address unmet clinical need and improve short-term survival rates.
There are approx. 5+ key companies which are developing the therapies for Acute Liver Failure. The companies which have their Acute Liver Failure drug candidates in the most advanced stage, i.e. phase II include Promthera Biosciences.
Route of Administration
Molecule Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Liver Failure therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Liver Failure drugs.
Geography Covered
- Global coverage
Acute Liver Failure Understanding
Acute Liver Failure: Overview
Acute liver failure is an uncommon condition in which rapid deterioration of liver function results in coagulopathy. Acute liver failure is loss of liver function that occurs rapidly - in days or weeks. Acute liver failure, also known as fulminant hepatic failure, can cause serious complications, including excessive bleeding and increasing pressure in the brain. Signs and Symptoms of Acute liver failure include: pain in right abdomen, yellowing of skin, nausea, vomiting, sleepiness and disorientation of confusion. Tests and procedures used to diagnose acute liver failure include: blood tests and imaging tests for the examination of liver. When acute liver failure cannot be reversed the only treatment may be the liver transplant.
"Acute Liver Failure - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wilson's Disease pipeline landscape is provided which includes the disease overview and Acute Liver Failure treatment guidelines. The assessment part of the report embraces, in depth Acute Liver Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Liver Failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Acute Liver Failure R&D. The therapies under development are focused on novel approaches to treat/improve Acute Liver Failure.
Acute Liver Failure Emerging Drugs Chapters
This segment of the Acute Liver Failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Acute Liver Failure Emerging Drugs
Hepastem: Promthera Biosciences
HepaStem is Promethera's lead cell therapy product currently in Phase 2 clinical trials for Acute Liver Failure. It consists of human allogeneic liver-derived medicinal signaling cells that are obtained from healthy, ethically donated organs and expanded in the manufacturing GMP factory. HepaStem is administered as a simple peripheral intravenous infusion, after which it is transported via the bloodstream to the liver, where it is expected to act as a cargo and activate multiple key pathogenetic pathways.
TAK-242: Akaza Biosciences
Akaza Bioscience is preparing to run a Phase II study of TAK-242, a novel immunological therapy. TAK-242 is an innovative, novel treatment option which aims to address unmet clinical need and improve short-term survival rates.
Acute Liver Failure: Therapeutic Assessment
This segment of the report provides insights about the different Acute Liver Failure drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Acute Liver Failure
There are approx. 5+ key companies which are developing the therapies for Acute Liver Failure. The companies which have their Acute Liver Failure drug candidates in the most advanced stage, i.e. phase II include Promthera Biosciences.
Phases
This report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Acute Liver Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Subcutaneous
- Intravenous
- Intramuscular
Molecule Type
Products have been categorized under various Molecule types such as
- Bispecific Antibody
- Peptides
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Acute Liver Failure: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Liver Failure therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Liver Failure drugs.
Acute Liver Failure Report Insights
- Acute Liver Failure Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Acute Liver Failure Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Acute Liver Failure drugs?
- How many Acute Liver Failure drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Liver Failure?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Liver Failure therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Acute Liver Failure and their status?
- What are the key designations that have been granted to the emerging drugs?
Table of Contents
IntroductionExecutive Summary
Acute Liver Failure: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Acute Liver Failure - Analytical Perspective
In-depth Commercial Assessment
- Acute Liver Failure companies' collaborations, Licensing, Acquisition -Deal Value Trends
Acute Liver Failure Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
- Comparative Analysis
ALXN1840: Alexion Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Bis-Choline Tetrathiomolybdate: Alexion Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
VTX-801: Vivet Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Preclinical Stage Products
- Comparative Analysis
Drug Name: Company name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Acute Liver Failure Key Companies
Acute Liver Failure Key Products
Acute Liver Failure- Unmet Needs
Acute Liver Failure- Market Drivers and Barriers
Acute Liver Failure- Future Perspectives and Conclusion
Acute Liver Failure Analyst Views
Acute Liver Failure Key Companies
AppendixList of Tables
Table 1 Total Products for Acute Liver Failure
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Acute Liver Failure
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Promthera Biosciences
- Akava Biosceinces
- Ticeba GmbH
- Tianjin Weikai Bioeng., Ltd
- HLB Cell Co., Ltd.
